ArticleProbiotics and antimicrobial proteins2026
Host-derived Pediococcus Acidilactici GLP06 Mitigates antibiotic-associated Diarrhoea in Dogs.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Multi-Omics Analysis Explores the Protective Effects and Potential Mechanisms ofBiomolecules · 2026Article
- Effects of a Low-Fat Diet Supplemented with Plant Extract on Lipid Metabolism, Antioxidant Capacity, Inflammation, and Gut Microbiota in Healthy Beagles.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibiotic-associated diarrhea (AAD) is an adverse reaction caused by antibiotic treatment, typically resulting from an imbalance in the gut microbiota. Probiotics have been widely used to counteract AAD by enhancing the composition of intestinal microbiota. Canine-derived Pediococcus acidilactic GLP06 has been shown to be a promising probiotic, however, the effect of P. acidilactici GLP06 on canine AAD is unknown. In this experiment, we investigated the effect of P. acidilactici GLP06 on antibiotic-induced diarrhea induced by intestinal flora imbalance in Beagle dogs by blood biochemical index test combined with 16s rRNA sequencing, SCFA test, and fecal untargeted metabolomics analysis. The results showed that probiotic administration significantly improved faecal scores, reduced serum diamine oxidase and tumour necrosis factor-α levels (p < 0.05), improved the intestinal barrier and inhibited intestinal inflammation. Importantly, after treatment with P. acidilactici GLP06, gut microbial diversity and richness gradually recovered, with a significantly increase in the number of Lactobacillus, Bifidobacterium, and Lachnospirales that produce short-chain fatty acids (SCFAs) (p < 0.05), and promoted the production of acetic acid, butyric acid, and total SCFAs in the gut (p < 0.05). In addition, metabolomics analysis showed that P. acidilactici GLP06 reversed the interference of antibiotics on major metabolic pathways such as purine metabolism, sphingolipid signaling pathway and bile secretion and increased the production of SCFAs, unsaturated fatty acids and glycocholic acid and other beneficial metabolites. These findings indicate that P. acidilactici GLP06 reversed the rupture of antibiotics on canine intestinal health by improving intestinal barrier function, regulating intestinal microbiota and restoring metabolic homeostasis, and effectively alleviated canine AAD. This provides scientific evidence for the potential use of P. acidilactici GLP06 as a probiotic for the prevention and treatment of canine AAD in future clinical applications.
Indexed as
Identifiers
41222846What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.